0001209191-22-039065.txt : 20220623
0001209191-22-039065.hdr.sgml : 20220623
20220623205757
ACCESSION NUMBER: 0001209191-22-039065
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220621
FILED AS OF DATE: 20220623
DATE AS OF CHANGE: 20220623
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Riga Thomas J
CENTRAL INDEX KEY: 0001726378
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35006
FILM NUMBER: 221036751
MAIL ADDRESS:
STREET 1: 11500 S. EASTERN AVE., SUITE 240
CITY: HENDERSON
STATE: NV
ZIP: 89052
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SPECTRUM PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000831547
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930979187
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11500 S. EASTERN AVE., SUITE 240
CITY: HENDERSON
STATE: NV
ZIP: 89052
BUSINESS PHONE: 702-835-6300
MAIL ADDRESS:
STREET 1: 11500 S. EASTERN AVE., SUITE 240
CITY: HENDERSON
STATE: NV
ZIP: 89052
FORMER COMPANY:
FORMER CONFORMED NAME: NEOTHERAPEUTICS INC
DATE OF NAME CHANGE: 19960819
FORMER COMPANY:
FORMER CONFORMED NAME: AMERICUS FUNDING CORP
DATE OF NAME CHANGE: 19920703
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-06-21
0
0000831547
SPECTRUM PHARMACEUTICALS INC
SPPI
0001726378
Riga Thomas J
11500 S. EASTERN AVE., SUITE 220
HENDERSON
NV
89052
1
1
0
0
CEO & President
Common Stock, $0.001 par value
2022-06-21
4
A
0
405040
0.00
A
1213340
D
Common Stock, $0.001 par value
14139
I
By 401(k) plan
Stock Option (Right to Buy)
0.63
2022-06-21
4
A
0
1078500
0.00
A
2032-01-27
Common Stock
1078500
1078500
D
Stock Option (Right to Buy)
0.63
2022-06-21
4
A
0
1488940
0.00
A
2032-01-27
Common Stock
1488940
1488940
D
The restricted stock unit grant was approved by Spectrum Pharmaceuticals, Inc.'s ("Spectrum") board of directors on January 27, 2022, subject to stockholder approval of the Amended and Restated 2018 Long-Term Incentive Plan (the "Plan") under which the restricted stock unit was granted. Spectrum's stockholders approved the Plan on June 21, 2022.
The option grant was approved by Spectrum's board of directors on January 27, 2022, subject to stockholder approval of the Plan under which the option was granted. Spectrum's stockholders approved the Plan on June 21, 2022.
Represents options granted in connection with the reporting person's promotion to President and Chief Executive Officer.
One third of the aggregate amount of option shares shall vest on each of January 27, 2023, 2024 and 2025, respectively.
Represents the annual performance awards granted to the reporting person.
/s/ Keith M. McGahan, attorney-in-fact for Thomas J. Riga
2022-06-23